182 related articles for article (PubMed ID: 20398326)
1. Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ.
Menn P; Weber N; Holle R
Health Qual Life Outcomes; 2010 Apr; 8():39. PubMed ID: 20398326
[TBL] [Abstract][Full Text] [Related]
2. Correlations between disease-specific and generic health status questionnaires in patients with advanced COPD: a one-year observational study.
Wilke S; Janssen DJ; Wouters EF; Schols JM; Franssen FM; Spruit MA
Health Qual Life Outcomes; 2012 Aug; 10():98. PubMed ID: 22909154
[TBL] [Abstract][Full Text] [Related]
3. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease.
Solem CT; Sun SX; Sudharshan L; Macahilig C; Katyal M; Gao X
Int J Chron Obstruct Pulmon Dis; 2013; 8():641-52. PubMed ID: 24376348
[TBL] [Abstract][Full Text] [Related]
4. Comparison of health-related quality of life measures in chronic obstructive pulmonary disease.
Pickard AS; Yang Y; Lee TA
Health Qual Life Outcomes; 2011 Apr; 9():26. PubMed ID: 21501522
[TBL] [Abstract][Full Text] [Related]
5. Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities.
Wacker ME; Jörres RA; Karch A; Wilke S; Heinrich J; Karrasch S; Koch A; Schulz H; Watz H; Leidl R; Vogelmeier C; Holle R;
BMC Pulm Med; 2016 May; 16(1):70. PubMed ID: 27160582
[TBL] [Abstract][Full Text] [Related]
6. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?
Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU
Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446
[TBL] [Abstract][Full Text] [Related]
7. Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease.
Bae E; Choi SE; Lee H; Shin G; Kang D
BMC Pulm Med; 2020 Mar; 20(1):73. PubMed ID: 32293387
[TBL] [Abstract][Full Text] [Related]
8. A comparison between the EQ-5D and the SF-6D in patients with chronic obstructive pulmonary disease (COPD).
Chen J; Wong CK; McGhee SM; Pang PK; Yu WC
PLoS One; 2014; 9(11):e112389. PubMed ID: 25379673
[TBL] [Abstract][Full Text] [Related]
9. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
[TBL] [Abstract][Full Text] [Related]
10. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
[TBL] [Abstract][Full Text] [Related]
11. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.
Tramontano AC; Schrag DL; Malin JK; Miller MC; Weeks JC; Swan JS; McMahon PM
Med Decis Making; 2015 Apr; 35(3):371-87. PubMed ID: 25670839
[TBL] [Abstract][Full Text] [Related]
12. Measuring quality of life in COPD patients: comparing disease-specific supplements to the EQ-5D-5L.
Szentes BL; Schwarzkopf L; Kirsch F; Schramm A; Leidl R
Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):523-529. PubMed ID: 31512524
[No Abstract] [Full Text] [Related]
13. Estimating the burden of disease in chronic pain with and without neuropathic characteristics: does the choice between the EQ-5D and SF-6D matter?
Torrance N; Lawson KD; Afolabi E; Bennett MI; Serpell MG; Dunn KM; Smith BH
Pain; 2014 Oct; 155(10):1996-2004. PubMed ID: 25020004
[TBL] [Abstract][Full Text] [Related]
14. Associations between the EQ-5D-5L and exacerbations of chronic obstructive pulmonary disease in the ETHOS trial.
Jackson D; Jenkins M; de Nigris E; Purkayastha D; Patel M; Ouwens M
Qual Life Res; 2024 Apr; 33(4):1029-1039. PubMed ID: 38206455
[TBL] [Abstract][Full Text] [Related]
15. Do We Need to Assess Quality-of-Life with Both the St George's Respiratory Questionnaire and the EuroQol 5-Dimension Questionnaire in a Clinical Study with an Economic Component: Insights from the REVOLENS Study in Severe Emphysema.
Bulsei J; Pfister J; Leroy S; Perotin JM; Barbe C; Marquette CH; Deslee G; Durand-Zaleski I;
Int J Chron Obstruct Pulmon Dis; 2020; 15():135-142. PubMed ID: 32021152
[TBL] [Abstract][Full Text] [Related]
16. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.
Kontodimopoulos N; Argiriou M; Theakos N; Niakas D
Eur J Health Econ; 2011 Aug; 12(4):383-91. PubMed ID: 20473544
[TBL] [Abstract][Full Text] [Related]
17. Comparison between the EQ-5D-3L and the SF-6D quality of life (QOL) questionnaires in patients with chronic obstructive pulmonary disease (COPD) undergoing lung volume reduction surgery (LVRS).
Thuppal S; Markwell S; Crabtree T; Hazelrigg S
Qual Life Res; 2019 Jul; 28(7):1885-1892. PubMed ID: 30707368
[TBL] [Abstract][Full Text] [Related]
18. Comparison of EQ-5D and SF-6D utilities in Pompe disease.
Kanters TA; Redekop WK; Kruijshaar ME; van der Ploeg AT; Rutten-van Mölken MP; Hakkaart L
Qual Life Res; 2015 Apr; 24(4):837-44. PubMed ID: 25342117
[TBL] [Abstract][Full Text] [Related]
19. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
Cheung PWH; Wong CKH; Cheung JPY
Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
[TBL] [Abstract][Full Text] [Related]
20. Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D.
Szende A; Leidy NK; Ståhl E; Svensson K
Qual Life Res; 2009 Mar; 18(2):267-72. PubMed ID: 19105049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
